Browse the evidence

Among U.S. Pima Indians, subjects with type 2 diabetes had lower leptin than nondiabetic subjects (difference = 6.9 +/- 1.0 ng/ml, P < 0.002).

Diabetes management may involve monitoring leptin levels as part of metabolic health assessments.

Mexican Pima Indians had lower absolute leptin concentrations than U.S. Pima Indians, but higher after adjustment for percent body fat, waist circumference, age, and sex.

Understanding the influence of lifestyle and environment on leptin can guide dietary and activity recommendations.

The public health focus on fructose is argued against in the context of sugar's overall effects.

Public health initiatives should consider a broader perspective on sugar consumption rather than focusing solely on fructose.

Semaglutide treatment resulted in lower rates of non-CV death, primarily due to fewer infectious deaths (HR: 0.71; 95% CI: 0.51-0.98).

Reducing infectious deaths may be a significant benefit of semaglutide in this population.

Among participants who developed COVID-19, those treated with semaglutide had fewer COVID-19-related serious adverse events and deaths (HR: 0.66; 95% CI: 0.44-0.96).

Semaglutide may provide protective benefits against severe outcomes from COVID-19 in this population.

Plasma high-density lipoprotein and total and high molecular weight adiponectin were increased, and triglycerides and high-sensitivity C-reactive protein levels were reduced 1 year after RYGB or SG.

Practitioners can expect improvements in lipid profiles and inflammatory markers after RYGB or SG.

Testosterone replacement therapy (TR) increased pubic hair in 72.7% of adult male patients with Prader-Willi syndrome.

Practitioners may consider TR as a viable option to enhance secondary sexual characteristics in this population.

Understanding the hedonic mechanisms mediated by gut peptide action could advance development of potential therapeutic strategies for the treatment of obesity and its comorbidities.

Research on gut peptides may lead to new obesity treatments.

Active GLP-1 RA prescription was associated with a significant reduction in postoperative hematoma (RR: 0.440; P = 0.023).

Consideration of GLP-1 RA may help in minimizing hematoma risks in surgical patients.

Short-acting GLP-1 receptor agonists are associated with an increased risk of erosive reflux disease (ERD) with a hazard ratio (HR) of 1.215.

Clinicians should be cautious when prescribing short-acting GLP-1 RAs to patients with type 2 diabetes due to the increased risk of ERD.

Short-acting GLP-1 receptor agonists are associated with an increased risk of oesophageal stricture with a hazard ratio (HR) of 1.284.

Healthcare providers should monitor for signs of oesophageal stricture in patients using short-acting GLP-1 RAs.

Short-acting GLP-1 receptor agonists are associated with an increased risk of Barrett's esophagus with dysplasia with a hazard ratio (HR) of 1.505.

Clinicians should be aware of the potential risk of Barrett's esophagus with dysplasia in patients prescribed short-acting GLP-1 RAs.

There were no significant differences in hormonal responses (IGF-1 and testosterone) between the two training systems.

Practitioners can expect similar hormonal responses regardless of the resistance training system used.

GLP-1RAs may have renal benefits driven by new-onset macroalbuminuria.

GLP-1RAs may be considered for patients with T2D who also have renal concerns, particularly regarding macroalbuminuria.

Perioperative semaglutide use is associated with increased residual gastric content (RGC) in patients undergoing elective esophagogastroduodenoscopy.

Clinicians should consider the timing of semaglutide administration in relation to elective procedures to mitigate RGC risk.

The contribution of the GIP receptor-activating component of tirzepatide to its effects is uncertain.

Further research is needed to clarify how GIP receptor activation contributes to the effects of tirzepatide.

Baseline muscle protein synthesis (MPS) during androgen deprivation therapy (ADT) is suppressed relative to age-matched controls.

Practitioners should be aware that ADT may lead to reduced muscle protein synthesis in patients.

GLP-1 RAs showed long-term protective effects on renal outcomes and adverse events.

GLP-1 RAs may provide long-term benefits for kidney health in obese individuals without T2D.

In patients with cardiometabolic HFpEF, tirzepatide showed a 58% lower risk of hospitalization for heart failure or all-cause mortality compared with sitagliptin.

Tirzepatide may also be a beneficial treatment option for patients with HFpEF and cardiometabolic conditions.

Low responders displayed higher plasma leptin levels compared with high responders at baseline.

Understanding leptin levels can help tailor interventions for different responder types.

GLP-1-RAs are known to delay gastric emptying.

Understanding the effect of GLP-1-RAs on gastric emptying is crucial for perioperative management.

Ghrelin and PYY changed significantly over time (p < 0.0001) but were not influenced by diet.

Dietary fat intake does not affect ghrelin and PYY levels in endurance-trained individuals.

Ghrelin was elevated during fasting, while insulin and PYY were suppressed.

Fasting increases ghrelin levels while decreasing insulin and PYY, which may influence appetite regulation.

Following exercise, PYY, ghrelin, and GH were significantly increased by ~11, ~16, and ~813%, respectively.

Exercise significantly increases levels of PYY, ghrelin, and GH, which may affect appetite and recovery.